Drug Trial Radar · NCT01924325
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Last checked: Nov 19, 2026Latest source record: Aug 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10,000
Planned (sponsor's estimate)
Start
Jan 2014
Primary completion
Dec 2015
Study completion Jul 2016
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin treatment reduced the risk of recurrent stroke and was not associated with increased hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants with less risk of bleeding events. To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized, double-blind, multicenter, controlled clinical trial has been designed. The investigators will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Conditions
- Ischemic Stroke
- TIA
Interventions
ApixabanDrug
orally active direct factor Xa inhibitor
ClopidogrelDrug
an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
AspirinDrug
a non-steroidal anti-inflammatory drug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- percentage of patients with new stroke (ischemic or hemorrhage)Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing Hospital
Xi'an, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.